Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on Doximity (DOCS) to $43 from $41 as estimates positioned for potential near-term upside. But upside to price target likely demands growth cadence that appears out of reach, Wells says, keeping the firm on the sidelines with an Equal Weight rating on the shares.